Kailera Therapeutics is trading 4.8% lower at $10.87; no verified source links the decline to a specific catalyst.
- The move follows a 3.91% gain on September 30.
- On October 1, the company presented new clinical data at EASD, including Phase 1 ribupatide injection-site findings; the report does not connect the data to the share move.
- The previous day’s Phase 3 enrollment announcement was positive development news, while broader indices were mixed.